AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Tryptamine Therapeutics Ltd gains A$6 million funding for clinical trials of TRP-8803.
- Major investors include the Merchant Biotech Fund and Dr. Daniel Tillett.
- Funds support expanded clinical trials on psilocin’s therapeutic potential.
Tryptamine Therapeutics Ltd (ASX:TYP), a clinical-stage biotechnology firm, has successfully raised A$6 million through a placement aimed at progressing its clinical trial strategy. The funding round, secured by commitments from professional, sophisticated, and institutional investors, will aid in advancing Tryptamine’s leading program, TRP-8803, an intravenous psilocin treatment under development for challenging psychiatric conditions.
The placement sees the issuance of 300 million new fully paid ordinary shares at A$0.02 per share. This significant capital infusion comes at a critical time, as Tryptamine’s TRP-8803 has shown promising outcomes in an early-stage Phase 1b study, achieving important safety benchmarks and providing the company with confidence as it moves toward larger trials. CEO Jason Carroll noted that the funds position Tryptamine with enhanced financial flexibility to advance its clinical agenda and explore the broader therapeutic potential of psilocin.
The Merchant Biotech Fund (MBF) and biotech expert Dr. Daniel Tillett anchor the new placement. Dr. Tillett, who will join Tryptamine’s board as a non-executive director, expressed enthusiasm for the company’s approach to developing safe, controlled psilocin treatments. He highlighted the potential of TRP-8803 in treating psychiatric illnesses that lack effective therapies, emphasizing psilocin’s unique neuroplasticity benefits, which could lead to long-term therapeutic effects.
With these funds, Tryptamine is preparing to initiate multiple new clinical trials early next year, focused on a diverse range of psychiatric applications. This milestone comes after Tryptamine’s recent progress, including its completion of safety-focused pathfinder trials for TRP-8802 and TRP-8803. These advancements build momentum as the company works to expand psilocin’s clinical applications and assess specific treatment opportunities in psychiatric care.
The new investment round also includes backing from Tryptamine’s significant shareholders, including Dr. Bill Garner, Herwig Janssen, and Ludwig Criel, alongside contributions from CEO Jason Carroll and company director Chris Ntoumenopoulos. Non-executive chair Mark Davies extended a warm welcome to new investors and expressed gratitude for the continued support of existing shareholders, emphasizing the near-term value Tryptamine aims to unlock as a leader in psychedelic drug development.
With added financial resources, Tryptamine is now positioned to further investigate the clinical impact of TRP-8803. The funds will allow the company to refine its dosing capabilities, ensuring safe and effective therapeutic experiences for patients.
